Surlorian clinical trials
How each study uses surlorian is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the surlorian studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test surlorian.
- Aug 2027A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related MyopathyPhase 2 · RyCarma Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses surlorian is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related MyopathyRecruitingPhase 2RyCarma Therapeutics, Inc.NCT07560020Written as Surlorian
- Treatment of an Inherited Ventricular ArrhythmiaTerminatedPhase 2Armgo Pharma, Inc.NCT05122975Written as S48168 (ARM210)
- S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM)CompletedPhase 1Armgo Pharma, Inc.NCT04141670Written as S48168
Codes
What other systems call surlorian · ClinicalTrials.gg INT014251
- UNII (FDA) 1033GN605LSURLORIANOne source FDA
- NCI Thesaurus C206994SurlorianOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1033GN605L | SURLORIAN | One source FDA |
| NCI Thesaurus | C206994 | Surlorian | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.